APMAdvances in Precision Medicine2424-85922424-9106WHIOCE PUBLISHING PTE. LTD.10.18063/APM.v11i3.1665ArticleAnalysis of the Efficacy and Safety of Modified Levator Palpebrae Superioris Muscle Shortening Surgery in the Treatment of Mild to Moderate Blepharoptosishttps://artdesignp.com/journal/APM/11/3/10.18063/APM.v11i3.1665ShenPeixing20261132026-03-26Objective: To analyze the clinical efficacy and safety of modified levator palpebrae superioris shortening in the treatment of mild to moderate blepharoptosis. Methods: A total of 78 patients with mild to moderate blepharoptosis admitted to our hospital from January 2023 to December 2024 were enrolled and divided into two groups using a random number table, with 39 cases in each group. The control group received conventional levator palpebrae superioris shortening, while the observation group was treated with modified levator palpebrae superioris shortening. The clinical efficacy, incidence of complications and recurrence rate at 6 months after surgery were compared between the two groups. Results: The total effective rates of the observation group and the control group were 94.87% and 79.49%, respectively (P < 0. 05). The incidence rates of complications (infection, failure of double eyelid fold formation, lagophthalmos and exposure keratitis) were 7.69% in the observation group and 25.64% in the control group. The recurrence rates at 6 months after surgery were 5.13% and 20.51%, respectively (P < 0.05). Conclusion: Modified levator palpebrae superioris shortening achieves a high clinical effectiveness rate in the treatment of patients with mild to moderate blepharoptosis. It can significantly improve postoperative upper eyelid position and eyelid opening-closing function, reduce complications such as infection and lagophthalmos, and present a low recurrence rate, demonstrating favorable clinical application value.Modified levator palpebrae superioris shortening,Blepharoptosis,Mild to moderate,clinical efficacy,Safety

[1] Ma Q, Hou M, Liu F, et al., 2025, A Surgical Method for Correcting Congenital Mild and Moderate Blepharoptosis. Journal of Tissue Engineering and Reconstructive Surgery, 21(2): 183–187. [2] Li JX, Xue H, Li X, et al., 2024, Analysis of Correction and Aesthetic Effects of Posterior Orbital Septum-Levator Palpebrae Superioris Complex Folding in Patients with Congenital Mild Blepharoptosis. Chinese Journal of Aesthetic Medicine, 33(9): 5–8. [3] Yang L, Wang H, Li XP, et al., 2025, Comparison of the Effect of “Floating Bridge” Technique and Levator Aponeurosis Shortening in the Treatment of Mild to Moderate Blepharoptosis. Chinese Journal of Aesthetic and Plastic Surgery, 36(9): 536–539. [4] Aksu CN, Yeniad B, 2022, Effects of Upper Eyelid Surgery on the Ocular Surface and Corneal Topography. Turkish Journal of Ophthalmology, 52(1): 50–56. [5] Dryden SC, Rho JE, Fowler SC, et al., 2021, Postoperative Clinical Outcomes Using Standard Variables Following Levator-Mullerectomy Advancement Blepharoptosis Surgery. Journal of Craniofacial Surgery, 32(6): e554–e556. [6] Li DM, 2021, Levator Palpebrae Superioris Shortening and Combined Fascial Sheath Suspension of Superior Rectus and Levator Palpebrae Superioris Muscles for Recurrent Blepharoptosis. Chinese Journal of Ophthalmology, 57(11): 813. [7] Expert Group for the Development of Expert Consensus on Diagnosis and Treatment of Blepharoptosis, 2017, Expert Consensus on Diagnosis and Treatment of Blepharoptosis. National Medical Journal of China, 97(6): 406–411. [8] Wang YX, Xie J, Wang W, 2023, Research Progress on the Pathogenesis and Surgical Methods of Congenital Blepharoptosis. Journal of Qiqihar Medical University, 44(13): 1253–1257. [9] Zhou R, Gao WC, 2022, Research Progress on the Pathogenesis of Senile Blepharoptosis. Journal of Tissue Engineering and Reconstructive Surgery, 18(3): 281–283. [10] Li JL, Yang C, Xing X, 2020, Research Progress of Blepharoptosis on Awakening. Chinese Journal of Aesthetic and Plastic Surgery, 31(5): 291–292. [11] Tan Y, Xu XS, Ni WQ, 2019, Observation on Levator Aponeurosis and Orbital Septal Fascia Composite Flap Advancement in Mild to Moderate Blepharoptosis. China Medical Cosmetology, 9(10): 18–21. [12] Chen Y, Qiu B, Chen KP, 2023, Analysis of Efficacy and Safety of Modified Levator Palpebrae Superioris Shortening in the Treatment of Mild to Moderate Blepharoptosis. China Medical Cosmetology, 13(7): 6–8. [13] Lu JF, Zhang GH, 2022, Observation on the Effect of Modified Levator Palpebrae Superioris Shortening and Advancement in the Treatment of Blepharoptosis. Zhejiang Medical Journal, 44(5): 519–522.